Deciding two connected writ petitions arising from a common Industrial Tribunal Award, the Delhi High Court set aside the Tribunal's direction granting hotel workmen a further…
Labour Laws
06/09/20264 min read
← back
Informative
Biotech Company Eyestems Valuation Surges 70% In Series B Round
Update / Judgement Date
08 Oct 2025
Source
Author
Sakshi Bhardwaj — WCP Legal Desk
Reading Time
1 min read
Investment BankingStart-Up & DPIIT
Eyestems, a biotech / life-sciences startup, saw its valuation jump ~70% in a recent Series B funding round. The article delves into the biotech’s research focus, IP, commercialization plans, preclinical / clinical pipeline, investor confidence, market potential (e.g. in ophthalmology or regenerative medicine), capital deployment plans, and the growing appetite for biotech investment in India.
